Predictive model of COVID-19 outcomes in patients with advanced HIV infection

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

BACKGROUND: No studies have examined the course and outcomes of coronavirus disease 2019 (COVID-19) in patients with advanced HIV infection, which prompted this analysis.

AIM: To identify predictors of the adverse outcomes of COVID-19 in patients with HIV at the stage of secondary diseases to develop a predictive model of outcomes. This will help simplify the decision-making on the management of patients with COVID-19 and HIV infection at advanced stages.

MATERIALS AND METHODS: This single-center study included 300 patients aged >18 years with HIV infection at advanced disease stage and moderate-to-severe COVID-19 requiring in-patient treatment.

RESULTS: The mortality rate was 27.3% (95% CI, 22.7%–32.4%). Factors reflecting respiratory failure, immunodeficiency, decreased levels of protein and albumin, and increased levels of urea became unfavorable. A predictive model of adverse outcomes of COVID-19 in patients with advanced HIV infection has been obtained.

CONCLUSIONS: The proposed predictive model can help a practical healthcare doctor make a quick, informed decision on hospitalization of a patient in the intensive care unit and active therapeutic actions.

作者简介

Anna Tsygankova

Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); Infectious Diseases Clinical Hospital No 2, Moscow

编辑信件的主要联系方式.
Email: anna.tsygankova.inf@gmail.com
ORCID iD: 0000-0003-3766-1868
SPIN 代码: 6583-0476

MD

俄罗斯联邦, Moscow; Moscow

Andrey Gerasimov

Central Research Institute of Epidemiology

Email: andr-gerasim@yandex.ru
ORCID iD: 0000-0003-4549-7172
SPIN 代码: 4742-1459
Scopus 作者 ID: 141741

Dr. Sci. (Phys.-Math.), Associate Professor

俄罗斯联邦, Moscow

Svetlana Potekaeva

Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); Infectious Diseases Clinical Hospital No 2, Moscow

Email: infection_mma@mail.ru
ORCID iD: 0000-0002-4771-9616
SPIN 代码: 6105-8492
Scopus 作者 ID: 493696

MD, Cand. Sci. (Med.)

俄罗斯联邦, Moscow; Moscow

Svetlana Krasnova

Infectious Diseases Clinical Hospital No 2, Moscow

Email: ikb2@zdrav.mos.ru
ORCID iD: 0000-0001-8592-5624
SPIN 代码: 3652-3811
Scopus 作者 ID: 1137169

MD, Cand. Sci.(Med.)

俄罗斯联邦, Moscow

Natalia Tsvetkova

Infectious Diseases Clinical Hospital No 2, Moscow

Email: 3655192@mail.ru
ORCID iD: 0000-0003-3323-3401
SPIN 代码: 5322-6167

MD, Cand. Sci. (Med.)

俄罗斯联邦, Moscow

Natalia Maloletneva

Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: natalya-maloletneva@yandex.ru
ORCID iD: 0000-0003-0430-731X
SPIN 代码: 8267-9750

MD, Cand. Sci. (Med.), Associate Professor

俄罗斯联邦, Moscow

Elena Volchkova

Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: antononina@rambler.ru
ORCID iD: 0000-0003-4581-4510
SPIN 代码: 3342-4681

MD, Dr. Sci (Med.), Professor

俄罗斯联邦, Moscow

Vladimir Chulanov

Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: vladimir.chulanov@rcvh.ru
ORCID iD: 0000-0001-6303-9293
SPIN 代码: 2336-4545

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Moscow

参考

  1. Pneumonia of unknown cause — China. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON229 Accessed: Nov 10, 2022
  2. WHO Director-General’s opening remarks at the media briefing on COVID-19 — 11 March 2020. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020/. Accessed: Nov 10, 2022.
  3. Shields AM, Anantharachagan A, Arumugakani G, et al. Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK. Clin Exp Immunol. 2022;209(3):247–258. doi: 10.1093/cei/uxac008
  4. Nomah DK, Reyes-Urueña J, Díaz Y, et al.; PISCIS study group. Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. Lancet HIV. 2021;8(11):e701–e710. doi: 10.1016/S2352-3018(21)00240-X
  5. HIV infection in the Russian Federation on December 31, 2021. Available from: http://www.hivrussia.info/wp-content/uploads/2022/03/Spravka-VICH-v-Rossii-na-31.12.2021-g..pdf. Accessed: Nov 10, 2022. (In Russ).
  6. On the epidemiological situation of HIV infection in the Russian Federation, the prevention of HIV infection at the workplace. Moscow: Rospotrebnadzor; 2019. (In Russ).
  7. Russia and countries of the world. 2020. Moscow: Rosstat; 2020. 385 p. (In Russ).
  8. Atyeo C, Fischinger S, Zohar T, et al. Distinct Early Serological Signatures Track with SARS-CoV-2 Survival. Immunity. 2020;53(3):524–532.e4. doi: 10.1016/j.immuni.2020.07.020
  9. Fenwick C, Joo V, Jacquier P, et al. T-cell exhaustion in HIV infection. Immunol Rev. 2019;292(1):149–163. doi: 10.1111/imr.12823
  10. Moir S, Fauci AS. B-cell responses to HIV infection. Immunol Rev. 2017;275(1):33–48. doi: 10.1111/imr.12502
  11. Lin KY, Wu PY, Liu WD, et al. Effectiveness of COVID-19 vaccination among people living with HIV during a COVID-19 outbreak. J Microbiol Immunol Infect. 2022;55(3):535–539. doi: 10.1016/j.jmii.2022.04.006
  12. Avdeev SN, Adamyan LV, Alekseeva EI, et al. Prevention, Diagnosis, and Treatment of Novel Coronavirus Infection (COVID-19): Interim Guidelines. Version 11 (05/07/2021). Moscow; 2021. 225 p. (In Russ).
  13. Avdeev SN, Adamyan LV, Alekseeva EI, et al. Prevention, Diagnosis, and Treatment of Novel Coronavirus Infection (COVID-19): Interim Guidelines. Version 12 (09/21/2021). Moscow; 2021. 232 p. (In Russ).
  14. Avdeev SN, Adamyan LV, Alekseeva EI, et al. Prevention, Diagnosis, and Treatment of Novel Coronavirus Infection (COVID-19): Interim Guidelines. Version 13 (10/14/2021). Moscow; 2021. 237 p. (In Russ).
  15. Avdeev SN, Adamyan LV, Alekseeva EI, et al. Prevention, Diagnosis, and Treatment of Novel Coronavirus Infection (COVID-19): Interim Guidelines. Version 14 (12/27/2021). Moscow; 2021. 233 p. (In Russ).
  16. Order of the Ministry of Health of the Russian Federation dated November 20, 2018 No. 802n “Ob utverzhdenii standarta pervichnoy mediko-sanitarnoy pomoshchi vzroslym pri bolezni, vyzvannoy virusom immunodefitsita cheloveka (VICH) (antiretrovirusnaya terapiya tret’yego ryada)”. Available from: https://www.garant.ru/products/ipo/prime/doc/72025248/. (In Russ).
  17. Gerasimov AN, Morozova NI. Parametric and Nonparametric Methods in Medical Statistics. Epidemiology and Vaccinal Prevention. 2015;14(5):6–12. (In Russ). doi: 10.31631/2073-3046-2015-14-5-6-12
  18. Gerasimov AN. Medical statistics. Moscow: MIA; 2007. 480 p. (In Russ).
  19. Bhaskaran K, Rentsch CT, MacKenna B, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. 2021;8(1):e24–e32. doi: 10.1016/S2352-3018(20)30305-2
  20. Moreno-Torres V, de Mendoza C, Martínez-Urbistondo M, et al. Predictors of in-hospital mortality in HIV-infected patients with COVID-19. QJM. 2022:hcac215. doi: 10.1093/qjmed/hcac215

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. ROC-curve for predicting lethal outcome.

下载 (250KB)
索引源数据

版权所有 © Eco-vector, 2022


 


##common.cookie##